Posts Tagged ‘patient outcomes’

Breath test for mesothelioma may be a future diagnostic tool

13 Jun 2017 by Sarah Mahan under Research/Treatment

upper body 944557 960 720 100x100 Breath test for mesothelioma may be a future diagnostic toolBreathalyzers are a staple for testing the sobriety of swerving drivers on the road, and now researchers in Belgium are trying to make a similar breath test a staple in mesothelioma treatment. (more…)


Cholesterol medication may help reduce healthy cell death in mesothelioma patients

6 Jun 2017 by Sarah Mahan under Research/Treatment

shutterstock 380260327 edited 100x100 Cholesterol medication may help reduce healthy cell death in mesothelioma patientsA cholesterol-lowering medication may be able to pull double duty to help mesothelioma patients, according to a group of Japanese researchers. The drug, pravastatin, has been shown to reduce damage to healthy cells when given to mice with mesothelioma before radiation treatments. (more…)


FitBits may be used to track mesothelioma patient outcomes

24 May 2017 by Sarah Mahan under Research/Treatment
Fitbit Charge HR 100x100 FitBits may be used to track mesothelioma patient outcomes

Credit: Wuefab/ Wikipedia

Asbestos exposure can cause a wide range of health issues, from lung-scarring asbestosis to mesothelioma. Many treatments for asbestos-related diseases can require extensive surgeries, and a large part of patient outcomes stems from how well patients recover from surgery, especially in the case of invasive procedures like removing a lung.

A new study by the Pacific Heart, Lung and Blood Institute’s (PHLBI) Pacific Mesothelioma Center is using FitBit devices to monitor patients’ progress after surgery, according to a news release. (more…)


SMRP biomarker can indicate pleural mesothelioma patient outcomes

22 May 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 11 100x100 SMRP biomarker can indicate pleural mesothelioma patient outcomesWhen biomarkers occur at elevated levels in the blood, they typically indicate disease, and testing for specific biomarkers helps doctors determine from which disease a patient is suffering. New research has shown a biomarker long used to diagnose malignant pleural mesothelioma may be a beneficial way to predict patient outcomes as well. (more…)


Elevated platelet count linked to negative peritoneal mesothelioma patient outcomes

7 Apr 2017 by Sarah Mahan under Research/Treatment

587px Researcher looks through microscope 1 100x100 Elevated platelet count linked to negative peritoneal mesothelioma patient outcomesThrombocytosis, a disorder that causes the body to produce too many blood platelets, has a negative impact on the success of a preferred treatment protocol for a number of mesothelioma patients, according to a new study by the University of Maryland School of Medicine. (more…)


Extrapleural pneumonectomy ‘clinically ineffective,’ group says

14 Mar 2017 by Sarah Mahan under Research/Treatment

lungs 1 002 100x100 Extrapleural pneumonectomy clinically ineffective, group saysA work group commissioned by the European Association for Cardio-Thoracic Surgery says enough evidence now exists to advise mesothelioma patients against extrapleural pneumonectomy (EPP). (more…)


Overall survival time is best clinical trial outcome measurement, study says

21 Feb 2017 by Sarah Mahan under Research/Treatment

598px Chemotherapy vials 3 100x100 Overall survival time is best clinical trial outcome measurement, study says Clinical trials are a vital part of medical testing, and their results determine treatment options for those diagnosed with an array of diseases. For those with mesothelioma, a deadly cancer caused by exposure to asbestos that affects the lining of the heart, lungs or abdomen, the results of clinical trials can determine how much longer a patient has to live.

A new study published in the journal The Oncologist stresses the important differences between two ways clinical trials determine outcomes for mesothelioma patients, according to Mesothelioma Research News. (more…)


New drug could reduce DNA modifications, improve mesothelioma patient outcomes

26 Jan 2017 by Sarah Mahan under Research/Treatment

640px DNA methylation 100x100 New drug could reduce DNA modifications, improve mesothelioma patient outcomes A new drug holds the potential to remove DNA modifications often associated with cancer cells and  decrease treatment resistance to improve patient outcomes.

Mesothelioma Research News reports drug 5-aza-dC has been found in a recent study to reduce DNA methylation, a common gene “signaling tool that locks the genes in the ‘off’ position,” according to Nature Education, and could possibly “improve the effectiveness of anti-cancer drugs and reduce the most aggressive mesothelioma cells that are often associated with treatment resistance.” (more…)


FASL gene along with platinum-based chemo could allow doctors to predict how long mesothelioma takes to progress, study says

5 Jan 2017 by Sarah Mahan under Research/Treatment

Catheter for chemotherapy 1 100x100 FASL gene along with platinum based chemo could allow doctors to predict how long mesothelioma takes to progress, study saysFor geneticists, the key to a person’s future is found on the microbiological level, and a recent Egyptian study has harnessed that insight to determine if certain genes can help predict mesothelioma patient outcomes.

Though multimodal treatment, including a combination of surgery, chemotherapy and radiation, can significantly improve a mesothelioma patient’s survival time, most diagnoses occur at later stages, when it is far too late for surgery and the talk turns to treatment options and how long a patient has to live.

Researchers in a new Egyptian study believe they have found a gene — FASL-844 CC — that can help predict how long a patient with mesothelioma can survive without disease progression, according to Mesothelioma Research News. (more…)